Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-23T06:24:54.583Z Has data issue: false hasContentIssue false

Smoking Cessation and Soft Signs of Mental Disorders

Published online by Cambridge University Press:  23 March 2020

A. Batra
Affiliation:
Psychiatry and Psychotherapy, Germany
S. Eck
Affiliation:
University Hospital, Psychiatry and Psychotherapy, Tubingen, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Smoking is associated with major depression, schizophrenia, anxiety and compulsive disorders, personality disorders, or substance abuse disorders [1,2]. More than that, smokers often report higher levels of novelty seeking, anxiety or depressive symptoms without fulfilling full diagnostic criteria for a psychiatric disorder.

In a former study, Batra et al. [3] had shown that smokers reporting higher levels of novelty seeking/hyperactivity, depressivity, and nicotine dependence evince higher relapse rates after completion of a six-weeks behavioural treatment program than smokers reporting low scores on self-report psychological symptom measures.

Another study [4] showed that a modified smoking cessation program matched to at-risk smokers’ needs with n = 268 adult smokers leads to higher long-term abstinence rates.

All at-risk smokers had been randomly assigned to receive either a standard or modified treatment. Best results were shown for smokers with mild depressive symptoms. The talk reports results of former and recent studies and focuses on the German treatment guidelines for tobacco related disorders.

These [5] recommend to assess tobacco use among patients with mental disorders and should be offered smoking cessation support under consideration of the acuteness and the particularities of the mental disorder using the same psychotherapeutic and pharmaceutical measures as for smokers without additional mental disorders.

Disclosure of interest

Financial support by Pfizer, Parexel, SKB, Novartis for smoking cessation studies.

Type
Symposium: Tobacco dependence and smoking cessation in people with mental illness
Copyright
Copyright © European Psychiatric Association 2017

References

Batra, A.Fortschr Neurol Psychiatr 2000; 68: 809210.1055/s-2000-11646CrossRefGoogle Scholar
Rüther, T.et al.European Psychiatry 2014; 29: 658210.1016/j.eurpsy.2013.11.002CrossRefGoogle Scholar
Batra, A., et al.JSAT 2008; 35: 4152Google Scholar
Batra, A., et al.JSAT 2010; 38: 128140Google Scholar
Batra, A., et al.SUCHT 2016; 62: 13915210.1024/0939-5911/a000423CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.